Form 4: Twist Bioscience CFO Sells Shares to Cover Tax Obligations

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,449 shares of common stock at $38.146 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), reported a sale of common stock.
• The transaction occurred on July 9, 2025.
• A total of 2,449 shares of common stock were disposed of at a price of $38.146 per share.
• Following this transaction, Adam Laponis beneficially owns 103,569 shares of common stock.
• The sale was a "sell to cover" transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations related to the vesting of Restricted Stock Units, and was not a discretionary trade.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is neutral in sentiment. It does not indicate a positive or negative view on the company's future performance by the insider.

Positives

• The sale was non-discretionary, indicating it was not based on a change in the CFO's outlook on the company's prospects.
• The transaction is a standard procedure for covering tax liabilities associated with equity compensation.

Negatives

• No specific negative aspects are indicated by this routine tax-related transaction.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing common across all industries for executives receiving equity compensation. It does not reflect broader industry trends but rather standard corporate compensation practices within the biotechnology or life sciences sector where Twist Bioscience operates.

Comparison to Industry Standards

• "Sell to cover" transactions are a standard and widely accepted method for executives across various industries to manage tax obligations arising from the vesting of equity awards, such as Restricted Stock Units (RSUs).
• This practice is consistent with how executives at comparable biotechnology companies, like Illumina (ILMN) or Pacific Biosciences of California (PACB), typically handle tax liabilities on their equity compensation.
• The volume of shares sold (2,449 shares) is relatively small compared to the total beneficial ownership (103,569 shares), which is typical for tax-related sales and does not suggest a significant change in the insider's overall investment in the company.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a non-discretionary sale for tax purposes and does not signal a change in management's confidence. The number of shares sold is a small fraction of the total outstanding shares.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider Trading, Adam Laponis, Chief Financial Officer, CFO, Stock Sale, Sell to Cover, Restricted Stock Units, Tax Withholding, Equity Compensation